Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07275905 · ClinicalTrials.gov registry record · Phase 1
Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection
A Phase 1 study, sponsored by Ghady Haidar.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07275905 is a Phase 1 study that has not yet begun recruiting, run by Ghady Haidar. The registered enrollment target is 12 participants.
The verdict
NCT07275905, a Phase 1 study, has not yet begun recruiting, sponsored by Ghady Haidar.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a new treatment called AchromoPhage is safe and well tolerated in adults with cystic fibrosis (CF) who have long-term lung infections caused by Achromobacter bacteria. AchromoPhage is a mixture of four naturally occurring viruses, called phages, that are designed to target and kill Achromobacter. This study will include 12 participants. People will be randomly assigned to one of three groups to receive AchromoPhage in different ways: by inhalation only, by intravenous (IV) infusion only, or by inhalation followed by IV infusion. Participants will: * Receive the study drug during clinic visits over a period of three weeks. * Provide blood, sputum, nasal, and oral samples so researchers can measure how the phages move through the body, how long they stay, and whether the body develops a response against them. * Complete breathing tests and quality-of-life questionnaires. The main question this study will answer is whether AchromoPhage causes any serious or treatment-limiting side effects in the first 42 days after dosing. Researchers will also look at changes in lung function, quality of life, phage levels in the body, and how the treatment affects Achromobacter and other bacteria in the lungs. The study is being run at the University of Pittsburgh (Pittsburgh, PA) and the University of California San Diego (San Diego, CA).
Interventions
- BIOLOGICAL AchromoPhage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07275905
The ClinicalTrials.gov registry entry for NCT07275905 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ghady Haidar, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AchromoPhage is the first listed.
NCT07275905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07275905 about?
NCT07275905 is a clinical study titled "Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection". The goal of this clinical trial is to learn if a new treatment called AchromoPhage is safe and well tolerated in adults with cystic fibrosis (CF) who have long-term lung infections caused by Achromobacter bacteria. AchromoPhage is a mixture of four naturally occurring viruses, called phages, that ar...
What is the current status of trial NCT07275905?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-05-01. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07275905?
The interventions under investigation include: AchromoPhage (BIOLOGICAL).
Who is sponsoring clinical trial NCT07275905?
This trial is sponsored by Ghady Haidar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.